Even Patients With Cancer in Remission at Risk for Severe COVID medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Major Advancement in Preventing Neutropenia, Says Trialist medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
As it plans to lower nitrate levels in groundwater for several counties, the Lower Elkhorn Natural Resources District hosted a virtual meeting to inform the public.
email article
Homologous recombination deficiency (HRD) predicted most responses to the PARP inhibitor olaparib (Lynparza) in patients with triple-negative breast cancer (TNBC), including patients without germline (
g)
PALB2 mutations, a small clinical trial showed.
Overall, 18 of 32 TNBCs responded to primary treatment with olaparib, and HRD was present in 16 of 18 responding tumors. A majority of responses occurred in tumors without germline mutations, in contrast to conventional wisdom about PARP inhibitors activity in breast cancer. Olaparib monotherapy yielded a high response rate when administered to treatment-naïve, large TNBC, with germline or somatic HR deficiency, reported Hans Petter Eikesdal, MD, of the University of Bergen in Norway, and colleagues in the
Lower Elkhorn NRD releases details on groundwater plans to deal with nitrate levels fremonttribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fremonttribune.com Daily Mail and Mail on Sunday newspapers.